John Henry Ashcraft DO
Associate Professor, General Surgery, University Kansas School of Medicine
Join to View Full Profile
4000 Cambridge StKansas City, KS 66160
Phone+1 913-588-2535
Fax+1 913-588-3867
Dr. Ashcraft is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Tennessee College of Medicine ChattanoogaResidency, Colon and Rectal Surgery, 2011 - 2012
University of Kansas School of MedicineResidency, Surgery, 2003 - 2008
University of Kentucky College of Medicine (Bowling Green)Internship, Transitional Year, 2002 - 2003
Kansas City University of Medicine and Biosciences College of Osteopathic MedicineClass of 2002
Certifications & Licensure
KS State License 2008 - 2026
American Board of Colon and Rectal Surgery Colon & Rectal Surgery
American Board of Surgery Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2015-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013, 2015-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013, 2015-2017
Publications & Presentations
PubMed
- Targeting FGFR Attenuates Tumor Growth in an Anal Squamous Cell Carcinoma Patient Derived Xenograft Model.Thuc Ly, Athena E Golfinos-Owens, Naren Raja, Levi Arnold, Pachiappan Arjunan
Molecular Carcinogenesis. 2025-07-01 - 7 citationsDoublecortin-like kinase 1 is a therapeutic target in squamous cell carcinoma.David Standing, Levi Arnold, Prasad Dandawate, Brendan Ottemann, Vusala Snyder
Molecular Carcinogenesis. 2023-02-01 - 9 citationsCo-localization of autophagy-related protein p62 with cancer stem cell marker dclk1 may hamper dclk1's elimination during colon cancer development and progression.Badal C. Roy, Ishfaq Ahmed, Satish Ramalingam, Venkatakrishna R. Jala, Bodduluri Haribabu
Oncotarget. 2019-03-22
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
